UMLS - Terms starting with ‘L’

	Medical glossary.
	MEDINDEX.AM UMLS About Catalog. Medical sites. UMLS.Semantic Types. Feedback

%
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z a c d e g h i

L L L- L0 L1 L6 LA LB LC LD LE LF LG LH LI LK LL LM LN LO LP LR LS LT LU LV LX LY

selected terms: 8,627

1 2 3 4 .. 87 Next >>

page 1 of 87

(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic Acid: [A hydrazine derivative of dopa. Carbidopa is a peripheral dopa decarboxylase inhibitor that is used as an adjunct to levodopa administration to prevent peripheral biosynthesis of levodopa to dopamine, thereby reducing peripheral side effects. Carbidopa does not penetrate the blood brain barrier so that levodopa, after it reaches the brain, can be metabolized to dopamine by dopa decarboxylase where it exerts its effect on dopamine receptors. ( NCI )] (UMLS (NCI) C0006982) =Organic Chemical; Pharmacologic Substance =[CN500] ANTIPARKINSON AGENTS;;hydrazine;;3-Hydroxy-alpha-methyl-L-tyrosine;; =CARBIDOPA 25 MG;;CARBIDOPA 50 MG;;CARBIDOPA 10 MG;;Carbidopa 12.5 MG / entacapone 200 MG / Levodopa 50 MG Oral Tablet;;CARBIDOPA 37.5 MG;;
(Laparoscopic) adjustment of size of adjustable gastric restrictive device: [ ] (UMLS (ICD9CM) C1456111) ADJUST GAST RESTRICT DEV;; =Therapeutic or Preventive Procedure
*Length Increment: (UMLS (HL7) C1547029) =Quantitative Concept =Kind of quantity;;
*Liquefaction: (UMLS (HL7) C1547030) =Quantitative Concept =Kind of quantity;;
125-L-Serine-2-133-interleukin 2: [A laboratory-made colony-stimulating factor that stimulates the production of blood cells, especially platelets, during chemotherapy. It is a cytokine that belongs to the family of drugs called hematopoietic (blood-forming) agents. Also called interleukin-2 or IL-2. ( NCI )] (UMLS (NCI) C0218986) =Amino Acid, Peptide, or Protein; Pharmacologic Substance ;; =[IM700] IMMUNE STIMULANTS;;Recombinant Protein =ALDESLEUKIN 22 MILLION UNT/VIL
15-Lipoxygenase, Reticulocyte Arachidonate: [Encoded by human ALOX15 Gene, a putative mutator gene regulated by tumor-suppressor TP53, 661-amino acid 74.7 kD cytoplasmic Arachidonate 15-Lipoxygenase (Lipoxygenase Family) acts in leukotriene biosynthesis and is implicated in anti-inflammation, membrane remodeling, and cancer development or metastasis. It converts arachidonic acid to 15s-hydroperoxyeicosatetraenoic acid. (OMIM, Swiss-Prot, and NCI) ( NCI )] (UMLS (NCI) C0003692) =Amino Acid, Peptide, or Protein; Enzyme
177 Lu-CC49: [A radioimmunoconjugate of the humanized monoclonal antibody (MoAB) CC49 labeled with lutetium 131 (Lu-177). MoAb CC49 binds to the pancarcinoma tumor-associated glycoprotein (TAG)-72 with high affinity. Lu-177 MoAb CC49 delivers gamma radiation emitting Lu-177 nuclide directly to tumor cells that express TAG-72, thereby may be used in radioimmunotherapeutic treatment of cancers. ( NCI )] (UMLS (NCI) C0935675) Lutetium Lu 177 Monoclonal Antibody CC49;; =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
2 lysophosphatidylcholine acylhydrolase: [An enzyme that catalyzes the hydrolysis of a single fatty acid ester bond in lysoglycerophosphatidates with the formation of glyceryl phosphatidates and a fatty acid. EC 3.1.1.5. ( MSH )] (UMLS (CSP) C0024361) =Amino Acid, Peptide, or Protein; Enzyme ;; =carboxylesterase;;
23-L-Leucinecolony-Stimulating Factor 2: [A colony-stimulating factor that stimulates the production of white blood cells, especially granulocytes and macrophages, and cells (in the bone marrow) that are precursors of platelets. It is a cytokine that belongs to the family of drugs called hematopoietic (blood-forming) agents. Also called granulocyte-macrophage colony-stimulating factor (GM-CSF). ( NCI )] (UMLS (NCI) C0216231) =Amino Acid, Peptide, or Protein; Pharmacologic Substance ;; =Colony-Stimulating Factor, Granulocyte-Macrophage;;[BL400] BLOOD FORMATION PRODUCTS =sargramostim 0.5 MG/ML;;SARGRAMOSTIM 500 MCG;;SARGRAMOSTIM 250 MCG
27-35(27L):MART-1: [A synthetic peptide consisting of amino acids 27 through 35 of the melanoma differentiation antigen MART-1. 27-35(27L) MART-1 has a leucine substitution at amino acid position 27 to improve binding to HLA-A*0201. Vaccination with this agent may stimulate the host immune response to mount a cytotoxic T-lymphocyte response against melanoma cells expressing MART-1. ( NCI )] (UMLS (NCI) C1710929) 27-35(27L):MART-1 Peptide =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
29-L-Argininamide-30-de-L-glutamine-31-de-L-glutamine-32-deglycine-33-de-L-glutamic acid-34-de-L-serine-35-de-L-asparagine-36-de-L-glutamine-37-de-L-glutamic acid-38-de-L-arginine-39-deglycine-40-de-L-alanine-41-de-L-arginine-42-de-L-alanine-43-de-L-argin: [The acetate salt form of sermorelin, a synthetic, amidated 29-amino acid peptide that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH). Sermorelin acetate directly stimulates the pituitary gland, resulting in release of growth hormone leading to increased plasma growth hormone, which is responsible for many biological processes and counteracts growth hormone deficiency. ( NCI )] (UMLS (NCI) C0162725) =Amino Acid, Peptide, or Protein; Pharmacologic Substance ;; =GHRH;; =SERMORELIN ACETATE 50 MCG;;SERMORELIN ACETATE 1 MG;;SERMORELIN ACETATE 0.5 MG
29060 LE: (UMLS (NCI) C1522610) 29060-LE;; =Organic Chemical; Pharmacologic Substance
37LRP: [Human RPSA wild-type allele is located in the vicinity of 3p22.2 and is approximately 6 kb in length. This allele, which encodes 40S ribosomal protein SA, plays a role in a variety of biological processes that are mediated by interactions with cell surface receptors. ( NCI )] (UMLS (NCI) C1705231) 67LR;;LAMBR;;LAMR1;;LAMR1 Gene;;LRP;;p40;;Ribosomal Protein SA wt Allele;;RPSA wt Allele;; =Gene or Genome
APETITU GALTZEA(ESKL. T06): (UMLS (ICPC) C1971624) (Loss of appetite; APETITU GALTZEA(ESKL. T06); Nedsat appetit; Verminderde eetlust; RUOKAHALUTTOMUUS; Perte d'appetit; Appetitlosigkeit; ibud teavon; etvagytalansag; Perdita di appetito; NEDSATT MATLYST; Perca de apetite; Perdida del apetito; APTITLOSHET) Appetitlosigkeit; APTITLOSHET; etvagytalansag; ibud teavon; Loss of appetite; Nedsat appetit; NEDSATT MATLYST; Perca de apetite; Perdida del apetito; Perdita di appetito; Perte d'appetit; =Finding ;; =ENDOCRINE, METABOLIC AND NUTRITIONAL; Symptoms and Complaints Component
L: [Mandibular left first primary molar ( HL7V3.0 )] (UMLS (HL7) C0227103) =Body Part, Organ, or Organ Component =Primary dentition;;
L 2 GLYCEROPHOSPHATE OXIDASE POWDER FOR SOLUTION 75 UMG: [ ] (UMLS (RXNORM) C1584443) =Clinical Drug
L 694,458: [ ] (UMLS (CSP) C0950972) =Organic Chemical; Pharmacologic Substance
L 705,126: (UMLS (NCI) C0297632) =Organic Chemical; Pharmacologic Substance
L 735524: [ ] (UMLS (CSP) C0701104) =Organic Chemical; Pharmacologic Substance ;;
L 743726: (UMLS (NDFRT)) (C0387218) =Organic Chemical; Pharmacologic Substance ;; =oxazine;; =Efavirenz
L 778,123: [An anticancer drug that belongs to the family of drugs called enzyme inhibitors. It may inhibit the transformation of normal cells into cancer cells. ( NCI )] (UMLS (NCI) C0796327) L-778,123;;L-778123 =Organic Chemical; Pharmacologic Substance ;;
L cell: [cells from c3h mouse fibroblasts grown in tissue culture that can support replication of many types of viruses. ( CSP )] (UMLS (CSP) C0022827) =Cell ;; =cell line;;neoplastic cell
L form bacteria: [ ] (UMLS (CSP) C0597958) =Bacterium ;;
L iditol dehydrogenase: [An alcohol oxidoreductase which catalyzes the oxidation of L-iditol to L-sorbose in the presence of NAD. It also acts on D-glucitol to form D-fructose. It also acts on other closely related sugar alcohols to form the corresponding sugar. EC 1.1.1.14 ( MSH )] (UMLS (CSP) C0020809) =Amino Acid, Peptide, or Protein; Enzyme ;; =alcohol oxidoreductase;;
L iduronate: [ ] (UMLS (CSP) C0178445) =Carbohydrate; Biologically Active Substance
L iduronidase: [An enzyme that hydrolyzes iduronosidic linkages in desulfated dermatan. Deficiency of this enzyme produces Hurler's syndrome. EC 3.2.1.76. ( MSH )] (UMLS (CSP) C0020818) =Amino Acid, Peptide, or Protein; Enzyme ;;
L NMMA: [An amino acid derivative used to counteract high blood pressure caused by interleukin-2. ( NCI )] (UMLS (CSP) C0069477) =Amino Acid, Peptide, or Protein; Biologically Active Substance ;;
L selectin: [L-Selectin is a cell surface glycoprotein adhesion molecule that serves as a homing receptor for lymphocytes to lymph node high endothelial venules. The molecule is composed of multiple domains: one homologous to lectins, one to epidermal growth factor, and two to C3/C4 binding protein consensus repeat units. L-Selectin may also play a role in neutrophil adhesion to endothelium at sites of inflammation. A tissue-specific mucin-like endothelial glycoprotein appears to function as ligand for L-selectin, in the role of scaffold that presents carbohydrates to the L-selectin lectin domain. PLAUR is directly associated with the carbohydrate-binding domain of L-selectin in the membrane of neutrophils, an association analogous to that between PLAUR and beta-2 integrins. (from OMIM 153240 and NCI) ( NCI )] (UMLS (CSP) C0125090) =Amino Acid, Peptide, or Protein; Immunologic Factor; Receptor
L&H Cell: (UMLS (NCI) C1518068) Lymphocytic and Histiocytic Cell;;Lymphocytic and Histiocytic Reed-Sternberg Cell Variant;;Popcorn Cell;; =Cell
L-12717: (UMLS (NCI) C0124796) =Organic Chemical; Pharmacologic Substance ;;
L-3-(3,4-Dihydroxyphenyl)-2-methylalanine Ethyl Ester Hydrochloride: [The hydrochloride salt form of methyldopa, a phenylalanine derivate and aromatic amino acid decarboxylase inhibitor with antihypertensive activity. Methyldopa is a prodrug and is metabolized in the central nervous system. The antihypertensive action of methyldopa seems to be attributable to its conversion into alpha-methylnorepinephrine, which is a potent alpha-2 adrenergic agonist that binds to and stimulates potent central inhibitory alpha-2 adrenergic receptors. This results in a decrease in sympathetic outflow and decreased blood pressure. ( NCI )] (UMLS (NCI) C0304527) =Organic Chemical; Pharmacologic Substance =METHYLDOPATE;; =METHYLDOPATE HYDROCHLORIDE 50 MG/ML
L-377,202: [A substance that is being studied in the treatment of cancer. ( NCI )] (UMLS (NCI) C0879383) L-377202;; =Organic Chemical; Pharmacologic Substance ;;
L-5103: (UMLS (NCI) C0733661) =Organic Chemical; Antibiotic ;;
L-588357-0: (UMLS (NCI) C1524090) =Amino Acid, Peptide, or Protein; Pharmacologic Substance ;;
L-744,832: [A farnesyl transferase inhibitors. ( NCI )] (UMLS (NCI) C0384181) =Amino Acid, Peptide, or Protein; Pharmacologic Substance ;;
L-744,832/Paclitaxel: (UMLS (NCI) C1517680) =Therapeutic or Preventive Procedure ;;
L-754030: (UMLS (NCI) C0759820) =Organic Chemical; Pharmacologic Substance ;;
L-778,123/Paclitaxel: (UMLS (NCI) C0879293) =Therapeutic or Preventive Procedure
L-779,450: [A synthetic triarylimidazole with potential antineoplastic activity. As a Raf kinase inhibitor, L-779450 competes with ATP for binding to the Raf-1 and A-Raf catalytic sites, thus inhibiting their enzymatic activities and blocking various signal transduction pathways that depend on Raf-1 kinase (particularly the Ras-Raf-MEK-ERK cascade which is often up-regulated in neoplasms). (NCI04) ( NCI )] (UMLS (NCI) C1517681) L-779450;; =Organic Chemical; Pharmacologic Substance
L-791456: (UMLS (NCI) C1097007) =Organic Chemical; Pharmacologic Substance ;;
L-All 12: [ ] (UMLS (RXNORM) C1633968) =Organic Chemical; Pharmacologic Substance
L-All 12 NF: [ ] (UMLS (RXNORM) C1964398) =Organic Chemical; Pharmacologic Substance
L-Asnase: (UMLS (NCI) C1510952) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Enzyme
L-Aspartic Acid, N-(Phosphonoacetyl)-, Tetrasodium Salt (9CI): (UMLS (NCI) C1524122) L-Aspartic Acid, N-(Phosphonoacetyl)-tetrasodium Salt;;Sparfosate Tetrasodium =Organophosphorus Compound; Pharmacologic Substance
L-Caine 10 MG/ML Injectable Solution: [ ] (UMLS (RXNORM) C0707670) =Clinical Drug
L-CARN FUM/A-CARN HCL/FRUC/CA PACKET: [ ] (UMLS (RXNORM) C0873997) L-CARNITINE FUMARATE/ACETYLCARNITINE HCL/FRUC(NO STR)/CIT AC PACKET;;L-CARNITINE FUMARATE/ACETYLCARNITINE HCL/FRUCTOSE (STR UNSPEC)/CITRIC ACID ORAL PACKET;; =Clinical Drug
L-CARNITINE: [An amino acid derivative. Levocarnitine facilitates long-chain fatty acid entry into mitochondria, delivering substrate for oxidation and subsequent energy production. Fatty acids are utilized as an energy substrate in all tissues except the brain. (NCI04)(NCI)] (UMLS (NDFRT)) (C0087163) =Organic Chemical; Pharmacologic Substance; Vitamin =carnitine;;[TN900] THERAPEUTIC NUTRIENTS/MINERALS/ELECTROLYTES, OTHER;;TO BE DELETED INGREDIENT PREPARATIONS;; =CHOICE DM LIQUID,BOTTLE,1000ML;;L-CARNITINE 100 MG/L;;L-CARNITINE 35 MG/240ML;;L-CARNITINE 38 MG/240ML;;LEVOCARNITINE 200 MG/ML;;LEVOCARNITINE 250 MG;;LEVOCARNITINE 330 MG;;LEVOCARNITINE 500 MG;;LEVOCARNITINE 750 MG;;LEVOCARNITINE 1 GM/10ML
L-CARNITINE 100 MG/L: (UMLS (NDFRT)) (C1375195) =Clinical Drug =L-CARNITINE;; =PRO-PEPTIDE VHN LIQUID UNFLAVORED,250ML;;
L-Carnitine 1g/10mL single-dose oral solution: [ ] (UMLS (RXNORM) C0982780) L-Carnitine 1g/10mL single-dose oral solution (product);;LEVOCARNITINE 100MG/ML LIQUID (ML);;LEVOCARNITINE 1 GAL ORAL SOLUTION;;LEVOCARNITINE 1 GM ORAL SOLUTION;;LEVOCARNITINE 1 GM ORAL SOLUTION [L];;LEVOCARNITINE 10 %VV ORAL SOLUTION;;LEVOCARNITINE 100 MG/ML Oral (systemic) solution;;LEVOCARNITINE 100 mg/mL ORAL LIQUID (ML);;levocarnitine 100 mg/ml oral solution;;LEVOCARNITINE 100MG/ML LIQUID (ML);;LEVOCARNITINE 100MG/ML ORAL LIQUID;;LEVOCARNITINE 100MG/ML ORAL LIQUID (ML);;Levocarnitine 1g/10mL solution;;Levocarnitine 1g/10mL solution (product);;LEVOCARNITINE 1GM/10ML LIQUID;;Levocarnitine Oral Soln 10%;;LEVOCARNITINE100 mg/mLORALLIQUID (ML);;LEVOCARNITINE100MG/MLORALLIQUID (ML);; =Clinical Drug =LEVOCARNITINE 1 GM/10ML;;
L-CARNITINE 35 MG/240ML: (UMLS (NDFRT)) (C1375196) =Clinical Drug =L-CARNITINE;; =MAGNACAL RENAL LIQUID,CAN,240ML;;
L-CARNITINE 38 MG/240ML: (UMLS (NDFRT)) (C1375197) =Clinical Drug =L-CARNITINE;; =CHOICE DM LIQUID,ORAL,CAN,240ML;;
L-CARNITINE FUMARATE 200MG CAPSULE (HARD, SOFT, ETC.): [ ] (UMLS (RXNORM) C1177892) L-CARNITINE FUMARATE 200MG ORAL CAPSULE (HARD, SOFT, ETC.);;L-CARNITINE FUMARATE200MGORALCAPSULE (HARD, SOFT, ETC.);;Levocarnitine 200 MG Oral Capsule;; =Clinical Drug
L-CARNITINE/CHROM/PARS/BEARBER TABLET: [ ] (UMLS (RXNORM) C1359715) LEVOCARNITINE/CHROMIUM/PARSLEY/BEARBERRY TABLET =Clinical Drug
L-CARNITINE/GOTU KO/BRIND BER 500-50-15 TABLET: [ ] (UMLS (RXNORM) C1358916) LEVOCARNITINE/GOTU KOLA/BRINDALL BERRY 500-50-15 TABLET;; =Clinical Drug
L-CARNITINE/MAG PIDO/BCOMP&C PACKET: [ ] (UMLS (RXNORM) C1348935) LEVOCARNITINE/MAGNESIUM PIDOLATE/VITAMIN B COMP W-C PACKET;;LEVOCARNITINE/MAGNESIUM PIDOLATE/VITAMIN B COMP W-C PACKET =Clinical Drug
L-Cell Glucagon-Like Peptide Producing Neoplasm: (UMLS (NCI) C1334328) L-Cell Glucagon-Like Peptide Producing Tumor =Neoplastic Process ;;
l-Deprenyl: [A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl. ( MSH )] (UMLS (NCI) C0036579) =Organic Chemical; Pharmacologic Substance ;; =[CN500] ANTIPARKINSON AGENTS;;Phenethylamines =(-)-Phenylisopropylmethylpropynylamine;;
L-DESOXYEPHEDRINE 50MG INHALER (EA): [ ] (UMLS (RXNORM) C0874338) L-DESOXYEPHEDRINE 50MG NASAL INHALER (EA);;L-DESOXYEPHEDRINE50MGNASALINHALER (EA);; =Clinical Drug
L-Dromoran: [ ] (UMLS (RXNORM) C0813471) =Organic Chemical; Pharmacologic Substance ;;
L-Dromoran 2 MG Oral Tablet: [ ] (UMLS (RXNORM) C0707506) =Clinical Drug
L-Dromoran 2 MG/ML Injectable Solution: [ ] (UMLS (RXNORM) C0707508) =Clinical Drug
L-Formula: [ ] (UMLS (RXNORM) C1724072) =Organic Chemical; Pharmacologic Substance
L-Formula 500 MG Oral Tablet: [ ] (UMLS (RXNORM) C1724075) (Lysine 500 MG Oral Tablet [L-Formula]) Lysine 500 MG Oral Tablet [L-Formula] =Clinical Drug ;;
L-GLUTAMIC ACID 5-ETHYL ESTER 100 %WW [L]: [ ] (UMLS (RXNORM) C1584444) =Clinical Drug
L-Glutamic Acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl): [A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis. ( NCI )] (UMLS (NCI) C0210657) =Organic Chemical; Pharmacologic Substance ;;
L-Gossypol: [The l-enantiomer of an orally-active polyphenolic aldehyde with potential antineoplastic activity. Derived primarily from unrefined cottonseed oil, l-gossypol inhibits the Bcl-2 family of proteins, resulting in induction of tumor cell apoptosis and inhibition of tumor cell proliferation. In vitro, this agent appears to be more potent than racemic gossypol or d-gossypol. ( NCI )] (UMLS (NCI) C1831823) =Organic Chemical; Pharmacologic Substance ;;
L-Methionine: [primary aminoacid with the side chain -CH2CH2SCH3, which, in the form of its S-adenosyl derivative (SAM), also serves as the principle methyl group donor of biosynthetic pathways. ( CSP )] (UMLS (NCI) C0025646) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Biologically Active Substance =Amino Acids, Essential;;Amino Acids, Sulfur;;Amino Acids, Neutral;;primary aminoacid;;Inactive Ingredient Preparations;; =5'-[(3-Amino-3-carboxypropyl)methylsulfonio]-5'-deoxyadenosine Hydroxide, Inner Salt;;RACEMETHIONINE;;Butanoic acid, 2-amino-4-(methylseleno)-;;METHIONINE POWDER (GM);;CRITICARE HN LIQUID;;METHIONINE 500 MG;;METHIONINE 200 MG;;METHIONINE 0.25 GM;;METHIONINE 0.45 GM;;METHIONINE 0.6 MG/ML;;METHIONINE 0.60 MG/ML;;METHIONINE 0.73 MG/ML;;METHIONINE 0.86 MG/ML;;METHIONINE 1.2 MG/ML;;METHIONINE 1.46 MG/ML;;METHIONINE 1.72 MG/ML;;METHIONINE 1.8 MG/ML;;METHIONINE 100 MG/100ML;;METHIONINE 125 MG/100ML;;METHIONINE 13.75 MG;;METHIONINE 140 MG/100ML;;METHIONINE 160 MG;;METHIONINE 2.06 MG/ML;;METHIONINE 2.8 MG/ML;;METHIONINE 200 MG/100ML;;METHIONINE 203 MG;;METHIONINE 22 MG/GM;;METHIONINE 258 MG/100ML;;METHIONINE 280 MG;;METHIONINE 3.4 MG/ML;;METHIONINE 318 MG;;METHIONINE 318 MG/100ML;;METHIONINE 340 MG;;METHIONINE 4.5 MG;;METHIONINE 400 MG;;METHIONINE 400 MG/100ML;;METHIONINE 450 MG/100ML;;METHIONINE 492 MG;;METHIONINE 492 MG/100ML;;METHIONINE 5.7 MG/ML;;METHIONINE 530 MG/100ML;;METHIONINE 7.49 MG/ML;;METHIONINE 726 MG/100ML;;METHIONINE 880 MG;;METHIONINE 25 MG
L-METHYLFOLATE: [ ] (UMLS (RXNORM) C1337136) =Organic Chemical; Pharmacologic Substance
L-METHYLFOLATE / mecobalamin / Pyridoxal Oral Tablet: [ ] (UMLS (RXNORM) C1702969) =Clinical Drug ;;
L-METHYLFOLATE / mecobalamin / Pyridoxal Oral Tablet [Metanx]: [ ] (UMLS (RXNORM) C1703858) =Clinical Drug ;;
L-METHYLFOLATE / Riboflavin / Vitamin B 12 / Vitamin B6 Oral Tablet: [ ] (UMLS (RXNORM) C1618797) =Clinical Drug ;;
L-METHYLFOLATE / Riboflavin / Vitamin B 12 / Vitamin B6 Oral Tablet [Cerefolin]: [ ] (UMLS (RXNORM) C1617256) =Clinical Drug ;;
L-METHYLFOLATE / Vitamin B 12 / Vitamin B6 Oral Tablet: [ ] (UMLS (RXNORM) C1711803) =Clinical Drug ;;
L-METHYLFOLATE 2.8 MG: [ ] (UMLS (RXNORM) C1703442) =Clinical Drug
L-METHYLFOLATE 2.8 MG / mecobalamin 2 MG / Pyridoxal 25 MG Oral Tablet: [ ] (UMLS (RXNORM) C1702440) =Clinical Drug
L-METHYLFOLATE 2.8 MG / mecobalamin 2 MG / Pyridoxal 25 MG Oral Tablet [Metanx]: [ ] (UMLS (RXNORM) C1698427) (METHYLCOBALAMIN 2 MG ORAL TABLET, FILM COATED [METANX];;) METHYLCOBALAMIN 2 MG ORAL TABLET, FILM COATED [METANX];; =Clinical Drug ;;
L-METHYLFOLATE 2.8 MG / mecobalamin 2 MG / Pyridoxal 25 MG [Metanx]: [ ] (UMLS (RXNORM) C1703443) =Clinical Drug
L-METHYLFOLATE 2.8 MG / Vitamin B 12 2 MG / Vitamin B6 25 MG Oral Tablet: [ ] (UMLS (RXNORM) C1711804) =Clinical Drug ;;
L-METHYLFOLATE 5.6 MG: [ ] (UMLS (RXNORM) C1703826) =Clinical Drug
L-METHYLFOLATE 5.63 MG: [ ] (UMLS (RXNORM) C1620914) =Clinical Drug ;;
L-METHYLFOLATE 5.63 MG / Riboflavin 5 MG / Vitamin B 12 1 MG / Vitamin B6 50 MG Oral Tablet: [ ] (UMLS (RXNORM) C1618283) =Clinical Drug
L-METHYLFOLATE 5.63 MG / Riboflavin 5 MG / Vitamin B 12 1 MG / Vitamin B6 50 MG Oral Tablet [Cerefolin]: [ ] (UMLS (RXNORM) C1612615) =Clinical Drug
L-METHYLFOLATE 5.63 MG / Riboflavin 5 MG / Vitamin B 12 1 MG / Vitamin B6 50 MG [Cerefolin]: [ ] (UMLS (RXNORM) C1617766) =Clinical Drug ;;
L-METHYLFOLATE 7.5 MG: [ ] (UMLS (RXNORM) C1702945) =Clinical Drug ;;
L-METHYLFOLATE 7.5 MG Oral Tablet: [ ] (UMLS (RXNORM) C1697139) =Clinical Drug
L-METHYLFOLATE 7.5 MG [Deplin]: [ ] (UMLS (RXNORM) C1703436) =Clinical Drug
L-METHYLFOLATE Oral Tablet: [ ] (UMLS (RXNORM) C1702946) =Clinical Drug ;;
L-METHYLFOLATE Oral Tablet [Deplin]: [ ] (UMLS (RXNORM) C1702961) =Clinical Drug
L-Oddc: (UMLS (NCI) C1831645) =Organic Chemical; Pharmacologic Substance ;;
L-PAM/MePRDL: (UMLS (NCI) C0281314) =Therapeutic or Preventive Procedure ;;
L-PAM/MePRDL/VCR: (UMLS (NCI) C0279441) =Therapeutic or Preventive Procedure
L-PAM/MNI: (UMLS (NCI) C0280679) =Therapeutic or Preventive Procedure
L-PAM/PCB/VBL: (UMLS (NCI) C0211067) =Therapeutic or Preventive Procedure
L-PAM/PRDL: (UMLS (NCI) C0796401) Melphalan/Prednisolone;; =Therapeutic or Preventive Procedure
L-PAM/PRED: (UMLS (NCI) C0284383) =Therapeutic or Preventive Procedure
L-PAM/PRED/VCR: (UMLS (NCI) C0279514) =Therapeutic or Preventive Procedure
L-PAM/TAX: (UMLS (NCI) C0281608) =Therapeutic or Preventive Procedure ;;
L-PAM/TNF: (UMLS (NCI) C0281628) =Therapeutic or Preventive Procedure
L-PAM/TSPA: (UMLS (NCI) C0050572) =Therapeutic or Preventive Procedure
L-PAM/VCR: (UMLS (NCI) C0280991) =Therapeutic or Preventive Procedure

UMLS

1 2 3 4 .. 87 Next >>

MEDINDEX.AM

to main page

About • Catalog. Medical sites. • UMLS.Semantic Types. • Feedback

top of page